Lung Cancer and Immunity Markers.

Area of Science:

• Oncology
• Immunology
• Genomics

Background:

• Lung cancer treatment has advanced due to better understanding of tumor biology.
• Early detection and interception of lung cancer remain critical challenges.
• Genomics and computational biology offer new avenues for studying early lung carcinogenesis.

Purpose of the Study:

• To review immune changes and biomarkers in pulmonary premalignancy and early-stage non-small cell lung cancer.
• To highlight the concept of immunoediting in lung cancer evolution.
• To discuss systemic biomarkers and clinical efforts for lung cancer interception.

Main Methods:

• Review of recent studies on immune landscape in the tumor microenvironment.
• Analysis of immune changes and biomarkers in early lung carcinogenesis.
• Focus on immunoediting and protumor/antitumor immune responses.

Main Results:

• Protumor immune responses, including checkpoint inhibition and increased inhibitory immune cells, correlate with tumor progression.
• Reduced antitumor immune responses are associated with lung cancer progression.
• Systemic biomarkers for early lung cancer are being identified.

Conclusions:

• Understanding immune changes in early lung cancer is key for developing interception strategies.
• Novel strategies for cancer interception could revolutionize lung cancer treatment and outcomes.
• Further research into immune biomarkers and interception holds significant clinical promise.